Clinical trial
Oral CF101 and Methotrexate Treatment in Rheumatoid Arthritis Patients
NCT00280917 · Can-Fite BioPharma, Industry · Completed
Key facts
| NCT number | NCT00280917 |
|---|---|
| Title | Oral CF101 and Methotrexate Treatment in Rheumatoid Arthritis Patients |
| Official title | Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of Daily CF101 Administered Orally, When Added to Weekly Methotrexate, in Patients With Active Rheumatoid Arthritis |
| Lead sponsor | Can-Fite BioPharma, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Rheumatoid Arthritis |
| Intervention type | Drug |
| Interventions | CF101 |
| Enrollment | 254 |
| Start date | Jun 1, 2006 |
| Primary completion | Apr 1, 2007 |
| Completion | Apr 1, 2007 |
| First posted | Jan 24, 2006 |
| Last update posted | Sep 18, 2023 |
| Countries | Bulgaria, Israel, Poland, Romania, Serbia, Ukraine, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: